Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 8/20 | 0.59 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.59 |
| ▸ | IKZF2 | Q9UKS7 | 7/20 | 0.58 |
| ▸ | IKZF1 | Q13422 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.56 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27283201 | 0.90 | IKZF2 (0.48) | CRBNDDB1IKZF2IKZF1ALDH1A1 | |
| SCHEMBL31338411 | 0.90 | CRBN (0.57) | CRBNDDB1IKZF2IKZF1ALDH1A1 | |
| SCHEMBL31338087 | 0.87 | IKZF2 (0.54) | CRBNDDB1IKZF2IKZF1ALDH1A1 | |
| SCHEMBL31338220 | 0.85 | CRBN (0.63) | CRBNDDB1IKZF2IKZF1ALDH1A1 | |
| SCHEMBL31337987 | 0.85 | CRBN (0.63) | CRBNDDB1IKZF2IKZF1ALDH1A1 | |
| SCHEMBL31337993 | 0.85 | CRBN (0.60) | CRBNDDB1IKZF2IKZF1ALDH1A1 | |
| SCHEMBL20765247 | 0.84 | IKZF1 (0.78) | IKZF2IKZF1 | |
| SCHEMBL26759990 | 0.84 | CRBN (0.62) | CRBNDDB1IKZF2IKZF1ALDH1A1 | |
| SCHEMBL30144642 | 0.84 | CRBN (0.55) | CRBNDDB1IKZF2ALDH1A1CHRM2 | |
| SCHEMBL24288991 | 0.83 | CRBN (0.56) | CRBNDDB1IKZF2ALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217970-A1 | PHTHALIMIDO CEREBLON COMPLEX BINDERS AND TRANSCRIPTION FACTOR DEGRADERS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240217970-A1 | PHTHALIMIDO CEREBLON COMPLEX BINDERS AND TRANSCRIPTION FACTOR DEGRADERS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217970-A1 | PHTHALIMIDO CEREBLON COMPLEX BINDERS AND TRANSCRIPTION FACTOR DEGRADERS AND METHODS OF USE | CRBN, IKZF2, IKZF1 | CRBN 1/4885DDB1 276/4885IKZF2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.